Skip to main content
. 2014 Nov 9;41(1):85–93. doi: 10.1093/schbul/sbu157

Table 2.

Regional [18F]-FEPPA VTs in Gray and White Matter ROIs of Patients With Schizophrenia (SCZ) and Healthy Volunteers (HV)

Gray Matter ROI HV (n = 27) SCZ (n = 16) Model Diagnostic Effect Genetic Effect Age Effect
Adjusted Mean SE Adjusted Mean SE F (3,39) P F (1,39) P F (1,39) P F (1,39) P
V T Hippocampus 11.45 2.03 8.03 2.65 1.501 .230 1.045 .313 1.801 .187 0.997 .324
Medial prefrontal cortex 9.03 0.52 9.69 0.67 5.968 .002 0.602 .442 15.606 <.001 1.012 .321
Temporal cortex 9.59 0.60 9.78 0.78 5.101 .004 0.037 .847 14.173 .001 0.394 .534
Dorsolateral prefrontal cortex 9.51 0.57 9.83 0.76 4.521 .008 0.110 .742 11.472 .002 1.120 .296
Striatum 8.17 0.47 8.38 0.61 6.151 .002 0.075 .786 18.443 <.001 0.307 .583
V T, corrected for partial volume effect Hippocampus 13.08 2.02 9.19 2.63 1.570 .212 1.374 .249 2.227 .144 0.473 .496
Medial prefrontal cortex 13.10 0.77 13.76 1.00 5.460 .003 0.274 .604 15.869 <.001 0.057 .813
Temporal cortex 12.39 0.75 12.24 0.98 5.152 .004 0.014 .907 14.878 <.001 0.034 .854
Dorsolateral prefrontal cortex 13.90 0.84 13.56 1.10 3.905 .016 0.062 .804 11.397 .002 0.028 .869
Striatum 8.903 0.54 9.03 0.70 6.900 .001 0.020 .888 20.652 <.001 0.230 .634
White Matter ROI HV (n = 27) SCZ (n = 15) F (3,38) P F (3,38) P F (3,38) P F (3,38) P
V T Corpus callosum 7.05 0.82 6.05 1.10 1.127 .350 0.521 .475 2.071 .158 0.299 .588
Cingulum 8.60 1.06 7.37 1.43 2.066 .121 0.482 .492 3.414 .072 1.371 .249
SLF 7.37 0.63 6.52 0.85 1.624 .200 0.641 .428 2.559 .118 0.911 .346
PLIC 7.57 0.56 7.22 0.74 2.314 .092 1.208 .149 6.406 .016 0.400 .531

Note: Factorial ANOVA comparisons were performed for each ROI to compare differences between diagnostic groups, with genotype (HAB vs MAB) and age added as covariates. White matter data obtained from one subject from the SCZ group was excluded, since no reliable kinetic model fit could be achieved in the white matter ROIs (coefficient of variation [COV] > 50). [18F]-FEPPA, N-acetyl-N-(2-[18F]fluoroethoxybenzyl)-2-phenoxy-5-pyridinamine; HAB, high-affinity binder; MAB, mixed-affinity binder; PLIC, posterior limb of the internal capsule; ROI, regions of interest; SLF, superior longitudinal fasciculus. Significant values are provided in bold.